Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Waters Co. NYSE: WAT. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Waters stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
- Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
- Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
- Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.
Waters Price Performance
NYSE:WAT traded down $13.14 during mid-day trading on Tuesday, reaching $355.43. The stock had a trading volume of 560,995 shares, compared to its average volume of 455,183. Waters Co. has a one year low of $279.24 and a one year high of $423.56. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94. The firm has a 50 day moving average price of $386.70 and a two-hundred day moving average price of $373.25. The stock has a market capitalization of $21.12 billion, a P/E ratio of 33.19, a P/E/G ratio of 3.79 and a beta of 1.00.
Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. As a group, analysts expect that Waters Co. will post 12.86 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Waters by 15.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,587 shares of the medical instruments supplier's stock valued at $1,331,000 after buying an additional 482 shares in the last quarter. Barclays PLC lifted its position in Waters by 34.8% during the 3rd quarter. Barclays PLC now owns 159,995 shares of the medical instruments supplier's stock valued at $57,579,000 after acquiring an additional 41,339 shares during the period. Savant Capital LLC boosted its stake in Waters by 3.8% during the fourth quarter. Savant Capital LLC now owns 1,704 shares of the medical instruments supplier's stock worth $632,000 after acquiring an additional 63 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in Waters by 13.2% in the third quarter. Public Sector Pension Investment Board now owns 2,578 shares of the medical instruments supplier's stock worth $928,000 after purchasing an additional 300 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Waters by 7.1% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 421,691 shares of the medical instruments supplier's stock valued at $156,439,000 after purchasing an additional 27,801 shares in the last quarter. Institutional investors own 94.01% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Barclays raised Waters from an "underweight" rating to an "equal weight" rating and boosted their target price for the company from $360.00 to $415.00 in a research note on Monday, February 10th. KeyCorp upgraded Waters from a "sector weight" rating to an "overweight" rating and set a $460.00 price objective for the company in a research report on Monday. Wells Fargo & Company lifted their target price on shares of Waters from $415.00 to $420.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Baird R W upgraded shares of Waters from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 26th. Finally, Scotiabank raised shares of Waters from a "sector perform" rating to a "sector outperform" rating and raised their price target for the stock from $430.00 to $450.00 in a report on Thursday, February 13th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $401.31.
Get Our Latest Stock Report on WAT
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
Waters Company Profile
(
Get Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Stories
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
